NCT05492591

A Study Exploring Efficacy of Peginterferon in Patients With Herpes Zoster

A Multicenter, Randomized, Active-controlled, Dose-finding Phase II Clinical Study Evaluating the Safety and Efficacy of Peginterferon α1b for Injection in Patients With Herpes Zoster

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 50 (actual)
• Sponsor: Shanghai Institute Of Biological Products · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the efficacy, optimal dose and efficacy trend of multiple subcutaneous injections of peginterferon α1b in patients with herpes zoster, and provide support for phase III clinical trials.

Detailed description

This trial is a multicenter, randomized, active drug-controlled, dose-finding phase II clinical study. A total of 5 experimental groups and 1 positive drug control group were set up to evaluate the efficacy, optimal dose and efficacy trend of multiple subcutaneous injections of peginterferon α1b in patients with herpes zoster, and provide support for phase III clinical trials.

Conditions

• Herpes Zoster

Interventions

Type	Name	Description
DRUG	Peginterferon α1b	Injecting different doses of the peginterferon α1b into different groups of subjects.
DRUG	Peginterferon α1b with valacyclovir	Both valacyclovir tablets and different dose of peginterferon α1b plan to be used in different groups of subjects.
DRUG	Valacyclovir	Valacyclovir is a positive control drug.

Timeline

• Start date: 2022-10-11
• Primary completion: 2023-07-22
• Completion: 2023-07-22
• First posted: 2022-08-08
• Last updated: 2023-12-29

Locations

1 site across 1 country: China